Skip to main content

Cancer

Patients with rheumatoid arthritis (RA) who had a history of cancer did NOT have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found. #RheumNow https://t.co/jM9oiRzXUk https://t.co/XYnaalEfe2
Dr. John Cush @RheumNow( View Tweet )
Sep 27, 2021

No Recurrent Cancer Risk With Biologic Treatment of RA

MedPage Today
Sep 24, 2021

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article

FDA Review of Vaping Products Extended

Sep 09, 2021

The FDA has again extended its decision on whether the manufacturers of vaping products can market their e-cigarettes in the United States.



Previously, the manufacturers (Juul, Vuse and Blu) were given until September 2020 to submit data to the FDA on the use and safety of these

Read Article
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found. #RheumNow https://t.co/mEYtTl2WRs https://t.co/KTluamv9gj
Dr. John Cush @RheumNow( View Tweet )
Sep 09, 2021

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article
Pleased to share our study in A&R investigating rheum evaluation, immunomodulator use, and predictors of rheumatic immune-related adverse events (irAEs) after immune #checkpoint inhibitor use for cancer, led by @BusselKiki @BrighamResearch @DanaFarber https://t.co/6rnSfd08FB

Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )

Sep 06, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article
The FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co. https://t.co/jayl8ufPHn https://t.co/zNvPiVcdOM
Dr. John Cush @RheumNow( View Tweet )
Sep 02, 2021
Newly Revised Xeljanz Boxed Warning. New Changes highlighted in yellow. https://t.co/jayl8tYeiN https://t.co/5tXX00UgBD
Dr. John Cush @RheumNow( View Tweet )
Sep 01, 2021

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Sep 01, 2021

Today, Sept.1st, the FDA announced its decision regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

These safety concerns arise from

Read Article
Gut microbiome strongly influences irAE's in advanced melanoma pts taking checkpoint blockade targeting CTLA-4 and PD-1. Signatures for Bacteroides intestinalis & Intestinibacter bartlettii more grade 3+ irAE by inducing IL-1B https://t.co/rEHknJ3TSC

Dr. John Cush @RheumNow( View Tweet )

Aug 31, 2021

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

MedPage Today
Aug 24, 2021

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Read Article

Skin Involvement with HMGCR Necrotizing Myositis

Aug 04, 2021

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.



Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated

Read Article
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs). https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx
Dr. John Cush @RheumNow( View Tweet )
Aug 02, 2021

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

Jul 29, 2021

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Read Article

Arthritis as a Harbinger of Pediatric Cancer

Jul 15, 2021

Lancet Rheumatology has published a cohort analysis showing that a small but significant subset of children presenting with arthralgia or arthritis may have a pediatric malignancy.



This multicentre study sought to identify articular presentations of children manifesting

Read Article

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Jul 09, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jul 05, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article
Analysis of Ph 3 data Tofacitinib in Ulcerative Colitis shows no increase in Cancer; rates equal to that seen w/ Tofa in RA, PsA & other biologics in UC. In 1124 pts (2576 PtYrs) there were 20 cancers, excluding NMSC (IR, 0.75; 0.46–1.16) https://t.co/xiTIKYAtyY

Dr. John Cush @RheumNow( View Tweet )

Jun 28, 2021

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jun 25, 2021

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
Can Focus Score Predict Risk of Lymphoma in Sjogren's Patients? https://t.co/kBptqUx2XG https://t.co/8y1736Kj8T
Dr. John Cush @RheumNow( View Tweet )
Jun 22, 2021
Can the Focus Score predict Lymphoma in Sjogren’s syndrome? by Dr. Eric Dein ( @ejdein1 ) https://t.co/B5HN6ju3ru https://t.co/3MuXH66YqJ
Dr. John Cush @RheumNow( View Tweet )
Jun 09, 2021
×